21 CFR 111.260
What must the batch record include?
21 CFR 111.260 is the regulation titled “What must the batch record include?” in 21 CFR Part 111, Current Good Manufacturing Practice in Manufacturing, Packaging, Labeling, or Holding Operations for Dietary Supplements. Since 2021, 14 FDA warning letters have cited it.
- Letters citing it
- 14 since 2021
- Jan 1 to Oct 30, 2026
- 3 against 2 on the same dates in 2025
- Most often cited with
- 21 CFR 111.70, in 13 letters
- Closed out
- 14% of these letters have a published close-out
Letters citing it, by year issued
All are drug letters. 2026 runs to Oct 30, 2026. Pick a year to see its letters.
What FDA writes when it cites it
The finding headings that cite 21 CFR 111.260 most often, as written in the letters.
- 1 letterYou failed to establish a batch production record (BPR) that satisfies the requirements of 21 CFR 111.255 and 111.260. For example, the BPRs for the BP Nat Relief, 11 Lot **(b)(4)**, and Edema NatRelief 6, Lot…
- 1 letterYou failed to establish product specifications for the identity, purity, strength, and composition of the finished batch of the dietary supplement, and for limits on those types of contaminants that may adulterate, or…
- 1 letterYou failed to include necessary information in the batch production records (BPRs), as required in 21 CFR 111.260. Specifically, your “Colostrum **(b)(4)** Reports,” which you provided as your BPRs for your Colostrum-5…
The regulation
Read the text of 21 CFR 111.260 (eCFR, as of Sep 1, 2026)
The batch production record must include the following:
(a) The batch, lot, or control number:
(1) Of the finished batch of dietary supplement; and
(2) That you assign in accordance with § 111.415(f) for the following:
(i) Each lot of packaged and labeled dietary supplement from the finished batch of dietary supplement;
(ii) Each lot of dietary supplement, from the finished batch of dietary supplement, that you distribute to another person for packaging or labeling;
(b) The identity of equipment and processing lines used in producing the batch;
(c) The date and time of the maintenance, cleaning, and sanitizing of the equipment and processing lines used in producing the batch, or a cross-reference to records, such as individual equipment logs, where this information is retained;
(d) The unique identifier that you assigned to each component (or, when applicable, to a product that you receive from a supplier for packaging or labeling as a dietary supplement), packaging, and label used;
(e) The identity and weight or measure of each component used;
(f) A statement of the actual yield and a statement of the percentage of theoretical yield at appropriate phases of processing;
(g) The actual results obtained during any monitoring operation;
(h) The results of any testing or examination performed during the batch production, or a cross-reference to such results;
(i) Documentation that the finished dietary supplement meets specifications established in accordance with § 111.70(e) and (g);
(j) Documentation, at the time of performance, of the manufacture of the batch, including:
(1) The date on which each step of the master manufacturing record was performed; and
(2) The initials of the persons performing each step, including:
(i) The initials of the person responsible for weighing or measuring each component used in the batch;
(ii) The initials of the person responsible for verifying the weight or measure of each component used in the batch;
(iii) The initials of the person responsible for adding the component to the batch; and
(iv) The initials of the person responsible for verifying the addition of components to the batch;
(k) Documentation, at the time of performance, of packaging and labeling operations, including:
(1) The unique identifier that you assigned to packaging and labels used, the quantity of the packaging and labels used, and, when label reconciliation is required, reconciliation of any discrepancies between issuance and use of labels;
(2) An actual or representative label, or a cross-reference to the physical location of the actual or representative label specified in the master manufacturing record; and
(3) The results of any tests or examinations conducted on packaged and labeled dietary supplements (including repackaged or relabeled dietary supplements), or a cross-reference to the physical location of such results;
(l) Documentation at the time of performance that quality control personnel:
(1) Reviewed the batch production record, including:
(i) Review of any monitoring operation required under subpart E of this part; and
(ii) Review of the results of any tests and examinations, including tests and examinations conducted on components, in-process materials, finished batches of dietary supplements, and packaged and labeled dietary supplements;
(2) Approved or rejected any reprocessing or repackaging; and
(3) Approved and released, or rejected, the batch for distribution, including any reprocessed batch; and
(4) Approved and released, or rejected, the packaged and labeled dietary supplement, including any repackaged or relabeled dietary supplement.
(m) Documentation at the time of performance of any required material review and disposition decision.
(n) Documentation at the time of performance of any reprocessing.
Text from eCFR as of Sep 1, 2026.
Cited alongside it
Regulations that appear in the same letters as 21 CFR 111.260.
- 21 CFR 111.70What specifications must you establish?13 letters cite both
- 21 CFR 111.255What is the requirement to establish a batch production record?12 letters cite both
- 21 CFR 201.5Drugs; adequate directions for use12 letters cite both
- 21 CFR 111.75What must you do to determine whether specifications are met?11 letters cite both
- 21 CFR 101.36Nutrition labeling of dietary supplements8 letters cite both
- 21 CFR 101.4Food; designation of ingredients8 letters cite both
- 21 CFR 101.9Nutrition labeling of food8 letters cite both
- 21 CFR 111.210What must the master manufacturing record include?8 letters cite both
Latest letters citing it
The 3 letters citing 21 CFR 111.260 that FDA posted most recently.
- DrugsView Mineral BioSciences, LLCTotala Fulvic Ionic Mineral Complex and IonicellIssuedJun 5, 2026PostedJul 21, 2026
- DrugsView Imu-Tek Animal Health, IncorporatedColostrum-5 Capsules and Colostrum-5 PowderIssuedJun 5, 2026PostedJun 23, 2026
- DrugsView Meta Labs Pharmaceuticals, LLCDietary supplements and unapproved drugs sold onlineIssuedMay 15, 2026PostedJun 2, 2026
Put this kind of reading to
work on your own records.
Botable builds and runs a custom AI layer around the software you already use, so your team can do the job you hired them for.
Counts include every citation in a letter, as the Letters filter does. How this database is built.